摘要
目的探讨透解祛瘟颗粒联合阿比多尔对普通型新型冠状病毒肺炎的疗效以及对相关T细胞表达的影响。方法将确诊为普通型新型冠状病毒肺炎的患者73例随机分为治疗组(37例)和对照组(36例),对照组口服阿比多尔,治疗组在对照组基础上口服透解祛瘟颗粒。于治疗前后对中医证候积分、外周血的白细胞计数(WBC)、淋巴细胞绝对值(LYM)、LYM比值、C反应蛋白(CRP)、外周血CD4^+、CD8^+、CD4^+/CD8^+、CD45^+的表达进行比较,并比较两组患者的临床疗效。结果治疗后,治疗组患者中医证候积分明显减轻,淋巴细胞绝对值上调,CRP下调,差异有统计学意义(P<0.05);与对照组比较,治疗组增加LYM绝对值、下调CRP的作用优于对照组(P<0.05);两组的WBC计数、LYM比值治疗后无明显变化(P>0.05)。疾病初期,对照组CD4^+细胞计数先上调后下降,而治疗组上调后较平稳;两组CD8^+、CD45^+细胞计数均上调,组间比较无统计学意义(P>0.05)。治疗组CD4^+/CD8^+上升,对照组下降,组间比较有统计学意义(P<0.05)。结论早期及时使用透解祛瘟颗粒联合阿比多尔可以减轻新型冠状病毒肺炎患者的症状,调控相关T细胞计数的平衡,促进患者免疫功能恢复,有较好的临床疗效。
Objective To investigate COVID-19 and its related T cell expression in the treatment of Toujie Quwen granules and Arbidol. Methods Seventy three COVID-19 patients were collected and divided into 2 groups:the treatment group(n=37)and the control group(n=36). The control group was given oral medicine of Arbidol,and the treatment group was given Toujie Quwen granules and Arbidol. The TCM syndrome scores,peripheral blood WBC cell counts,LYM cell counts,LYM ratio,CRP,CD4^+,CD8^+,CD4^+/CD8^+and CD45^+were compared before and after treatments. Results After treatment, the TCM syndrome score of the treatment group was significantly reduced, the absolute value of lymphocyte was up-regulated, CRP was down regulated, the differences were statistically significant(P < 0.05,P < 0.05). Compared with the control group,the increase of LYM and decrease of CRP in the treatment group were better(P < 0.05,P < 0.05);there was no significant difference in WBC count and LYM ratio(P > 0.05). In the early stage,CD4^+in the control group decreased after a earlier up-regulation,and the expression of CD8^+and CD45^+in the treatment group was stable after up-regulation;there was no significant difference between the two groups(P > 0.05). CD4^+/CD8^+increased in the treatment group and decreased in the control group(P < 0.05). Conclusion Symptoms of COVID-19 patients could be alleviated by early and timely application of the combined solution of Toujie Quwen granules and Arbidol. The expression of T cell counts can be controlled and the immune function can be restored.
作者
傅晓霞
林路平
谭行华
FU Xiaoxia;LIN Luping;TAN Xinghua(Guangzhou Eighth People's Hospital,Guangzhou 510440 Guangdong,China)
出处
《中药新药与临床药理》
CAS
CSCD
北大核心
2020年第5期600-604,共5页
Traditional Chinese Drug Research and Clinical Pharmacology
基金
国家“十三五”重大专项“一带一路”传染病中医药临床诊疗方案推广应用(2018ZX10101001)
广东省防控新型冠状病毒感染科技攻关应急专项项目(2020B111115001)
广东省中医药局科研基金项目(20201271)。
